Revenue and Earnings - Revenue increased 11 percent to $226.8 billion for fiscal 2024, compared to $205.0 billion for fiscal 2023, primarily driven by growth in branded and specialty pharmaceutical sales[24]. - GAAP operating earnings for fiscal 2024 were $1.2 billion, a 65 percent increase from $752 million in fiscal 2023, influenced by segment profit increases[25][26]. - Non-GAAP operating earnings rose 16 percent to $2.4 billion in fiscal 2024, compared to $2.1 billion in fiscal 2023[25][28]. - GAAP diluted EPS increased to $3.45 in fiscal 2024 from $1.26 in fiscal 2023, while non-GAAP diluted EPS rose 29 percent to $7.53[30][34]. - The total consolidated operating earnings increased by 65% to $1.243 billion in fiscal 2024 compared to the previous year[70]. - Non-GAAP net earnings attributable to Cardinal Health, Inc. for fiscal year 2024 were $1,856 million, an increase of 21% from the prior year[177]. Cash and Investments - Cash and equivalents balance was $5.1 billion at June 30, 2024, up from $4.1 billion at June 30, 2023, with net cash provided by operating activities at $3.8 billion[35]. - The company deployed $1.2 billion for the Specialty Networks acquisition and $750 million for share repurchases during fiscal 2024[35]. - Share repurchases amounted to $750 million in fiscal 2024, down from $2.0 billion in fiscal 2023[113]. - Capital expenditures for fiscal 2024 were $511 million, with expectations for fiscal 2025 to be between $500 million and $550 million[111]. Segment Performance - Pharmaceutical and Specialty Solutions segment revenue increased by 11% in fiscal 2024, reaching $210.0 billion, driven by branded and specialty pharmaceutical sales growth[51]. - Global Medical Products and Distribution (GMPD) segment revenue grew by 1% to $12.4 billion in fiscal 2024, primarily due to higher volumes from existing customers[51]. - Segment profit for Pharmaceutical and Specialty Solutions increased by 7% to $2.015 billion in fiscal 2024, while GMPD segment profit improved to $92 million from a loss of $147 million in the previous year[70]. - Fiscal 2024 profit for the Pharmaceutical and Specialty Solutions segment increased primarily due to the positive performance of the generics program[71]. - Fiscal 2024 profit for the Global Medical Products and Distribution (GMPD) segment increased due to beneficial comparisons to prior-year inflationary impacts[72]. Organizational Changes - The updated organizational structure includes two reportable segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution[19]. - Effective January 1, 2024, the company implemented a new enterprise operating and segment reporting structure, comprising two reportable segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution[136]. Goodwill and Impairments - The company reported a pre-tax non-cash goodwill impairment charge of $675 million related to the GMPD segment for fiscal 2024[26][32]. - The company allocated $90 million of goodwill to the GMPD reporting unit, resulting in a full impairment of GMPD's remaining goodwill balance[48]. - Cumulative pre-tax goodwill impairment charges for the GMPD segment were $675 million, $1.2 billion, and $2.1 billion for fiscal years 2024, 2023, and 2022, respectively[159]. Litigation and Settlements - As of June 30, 2024, the company has accrued $5.4 billion related to opioid litigation, with expected payments continuing through 2038[109]. - The company accrued $363 million for opioid litigation as of June 30, 2024, reflecting the current estimate of probable loss[149]. - A settlement agreement for IVC filter product liability claims was executed for $275 million, resolving approximately 4,375 claims[150]. - The company continues to engage in resolution discussions regarding opioid litigation, with agreements in principle reached with various parties[149]. Future Outlook - Future outlook includes continued focus on enhancing supply chain efficiency and integrated care coordination across healthcare providers[18]. - The expiration of OptumRx contracts, which contributed 17% of consolidated revenue in fiscal 2024, is anticipated to negatively impact operating cash flow in fiscal 2025[39]. - The company expects inflationary impacts to continue affecting GMPD segment profit in fiscal 2025, although mitigation actions are anticipated to offset these costs[46]. Tax and Other Financial Metrics - The effective tax rate for non-GAAP earnings before income taxes was 21.7% for fiscal year 2024[177]. - The company recognized tax benefits related to goodwill impairment charges amounting to $58 million, $92 million, and $140 million for fiscal years 2024, 2023, and 2022, respectively[159]. - The allowance for doubtful accounts at the end of fiscal 2024 was $233 million, representing 1.9% of customer receivables[125]. Acquisitions and Divestitures - The company completed the acquisition of Specialty Networks for a purchase price of $1.2 billion in cash on March 18, 2024[96]. - The divestiture of the Cordis business in August 2021 generated net proceeds of $923 million in cash[210]. - Cardinal Health expects to continue exploring acquisitions in the future to support its brand medical products and specialty pharmaceutical products[204].

Cardinal Health (CAH) came out with quarterly earnings of $1.84 per share, beating the Zacks Consensus Estimate of $1.72 per share. This compares to earnings of $1.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.98%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $1.95 per share when it actually produced earnings of $2.08, delivering a surprise of 6.67%.Over the last four qua ...

Q4 FY24 Earnings Cardinal Health, Inc. August 14, 2024 © 2024 Cardinal Health. All Rights Reserved. 1 © 2024 Cardinal Health. All Rights Reserved. INTERNAL USE ONLY • Q4 FY24 Earnings Cautions Concerning Forward-Looking Statements This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "wi ...

As of Aug 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to ...

Q4 and full year FY24 summary 2 Exhibit 99.1 | | Q4 FY24 | Q4 FY23 | Y/Y | FY24 | FY23 | Y/Y | | --- | --- | --- | --- | --- | --- | --- | | Revenue | $59.9 billion | $53.4 billion | 12% | $226.8 billion | $205.0 billion | 11% | | Operating earnings/(loss) | $401 million | $111 million | N.M. | $1,243 million | $752 million | 65% | | Non-GAAP operating earnings | $605 million | $530 million | 14% | $2.4 billion | $2.1 billion | 16% | | Net earnings/(loss) attributable to Cardinal Health, | | | | | | | | Inc ...

Cardinal Health, Inc. CAH is set to release earnings results for its fourth quarter, before the opening bell on Aug. 14, 2024.Analysts expect the Dublin, Ohio-based company to report quarterly earnings at $1.73 per share, up from $1.55 per share in the year-ago period. Cardinal Health is expected to report quarterly revenue of $58.64 billion for the quarter, compared to $53.45 billion a year earlier, according to data from Benzinga Pro.On May 7, Cardinal Health approved an increase to its quarterly dividend ...

Cardinal Health, Inc. (CAH) is scheduled to report fourth-quarter fiscal 2024 results on Aug 14, before the opening bell.In the last reported quarter, the company delivered an earnings surprise of 6.67%. CAH’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 12.91%.Q4 EstimatesFor the fiscal fourth quarter, the consensus mark for earnings is pegged at $1.72 per share, indicating an improvement of 10.9% from the prior-year quarter’s reported ...

Analysts on Wall Street project that Cardinal Health (CAH) will announce quarterly earnings of $1.72 per share in its forthcoming report, representing an increase of 11% year over year. Revenues are projected to reach $58.72 billion, increasing 9.9% from the same quarter last year.Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forec ...

The market expects Cardinal Health (CAH) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be release ...

In the latest market close, Cardinal Health (CAH) reached $99.52, with a +1.18% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 1.04% for the day. Elsewhere, the Dow saw an upswing of 0.76%, while the tech-heavy Nasdaq appreciated by 1.03%.The prescription drug distributor's shares have seen an increase of 1.53% over the last month, surpassing the Medical sector's gain of 0.21% and the S&P 500's loss of 6.74%.The investment community will be closely monitori ...